Resources

Measure of Ovarian Symptoms and Treatment (MOST) 
MOST is a validated instrument that was developed by the GCIG to measure the impact of palliative chemotherapy on cancer related to symptoms as well as on symptoms related to adverse effects of treatment reported by patients receiving chemotherapy for recurrent ovarian cancer.

Watermarked MOST questionnaires and scoring instructions are provided here.  Access to editable MOST questionnaires are available after registration using the link at the bottom of the page.

• Measure of Ovarian Symptoms and Treatment – MOST-T35(v1) - Recommended to measure symptom benefit during chemotherapy for recurrent ovarian cancer.
• Measure of Ovarian Symptoms and Treatment – MOST-T24(v2) - Recommended to measure symptom benefit during chemotherapy for recurrent ovarian cancer, focusing on symptoms and well-being.
• Measure of Ovarian Symptoms and Treatment Surveillance (MOST-S26) - Recommended for surveillance following first line treatment.
• Scoring Instructions - MOST-T35(v1) & MOST-T24(v2) 

Registration to Access Editable MOST Questionnaires

Clinical Trials Pathology Manual-Guidelines (2018)

GCIG-ISGyP Meetings:

• Registration List - March 2018
• Summary - March 2018
• Registration List - March 2017
• Summary - March 2017
• Registration List - March 2016
• Summary - March 2016

Recent clinical questions posed to the group by GCIG members. Click the link to see full list of replies.